526 Rec'd PCT/PTO 16 JUL 2001

OZU INC U: FUI/F	10 10 30L 2001							
FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 11-2000)	ATTORNEY'S DOCKET NUMBER							
TRANSMITTAL LETTER TO THE UNITED STATES	Le A 33 364							
DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5							
CONCERNING A FILING UNDER 35 U.S.C. 371	09/889455							
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/EP00/00120 11 January 2000 (11.01.00)	15 January 1999 (15.01.99)							
TITLE OF INVENTION  Beta-Phenylalanine Derivatives as Integrin Antagonists								
APPLICANT(S) FOR DO/EO/US								
Schoop, et al.  Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.	,							
This is a <b>FIRST</b> submission of items concerning a fining under 35 U.S.C. 371.								
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
The US has been elected by the expiration of 19 months from the priority date (Article 31).								
A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a.								
b. has been communicated by the International Bureau.								
c. is not required, as the application was filed in the United States Receiving Office (RO/US).								
a. is attached hereto.								
b. has been previously submitted under 35 U.S.C. 154(d)(4).								
7. X Amendments to the claims of the International Aplication under PCT Article 19	Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))							
a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.	b. have been communicated by the International Bureau.							
c. have not been made; however, the time limit for making such amendr	c. have not been made; however, the time limit for making such amendments has NOT expired.							
d. X have not been made and will not be made.								
An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).								
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	•							
0. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 20 below concern document(s) or information included:								
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13. X A FIRST preliminary amendment.								
14. A SECOND or SUBSEQUENT preliminary amendment.								
15. A substitute specification.								
A change of power of attorney and/or address letter.								
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.								
18. A second copy of the published international application under 35 U.S.C. 154	A second copy of the published international application under 35 U.S.C. 154(d)(4).							
A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
Other items or information:1) Certificate of Mailing under 37 C.F.R. 1.10; 2) Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b);								
<ul><li>3) Information Disclosure Citation (Modified Fo</li><li>4) Return Receipt Postcard.</li></ul>	rm PTO-1449) and references cited thereir							
Date of Deposit: JUL 1 6 2001 Express Mail Label No.: EF349742063US								



JC03 Rec'd PCT/PTC 1 6 JUL 2001

Cardina Valore Car	ナギンジ		P00/00120		Le A 33 364		
21. X The follow	ing fees are subm	itted:			CALCULATIONS	PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):							
Neither international preliminary examination fee (37 CFR 1.482)							
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO							
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00							
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)							
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00							
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 860.00				
			□ 20 □ 30	- 000.00	<u> </u>		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					\$		
CLAIMS .	NUMBER FIL	ED NU	MBER EXTRA	RATE	\$		
Total claims	<b>16</b> - 20	=	0	x \$18.00	\$ 0.00		
Independent claims	<b>5</b> - 3		2	x \$80.00	\$ 160.00		
MULTIPLE DEPEN		· · · · · · · · · · · · · · · · · · ·	,	+ \$270.00	\$ 0.00		
			BOVE CALCU		\$ 1,020.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$			
				JBTOTAL =	\$ 1,020.00		
Processing fee of \$130.00 for furnishing the English translation later than  20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$				
TOTAL NATIONAL FEE =			\$ 1,020.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$				
TOTAL FEES ENCLOSED =				\$ 1,020.00			
	<del>-</del> .				Amount to be refunded:	\$	
					charged:	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.  b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 1,020.00 to cover the above fees.							
A duplicate copy of this sheet is enclosed.							
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372 . A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPO	ONDENCE TO:			( )CAL	ie L. Ch	ue	
Jeffrey M. Greenman SIGNATURE							
Vice President, P Bayer Corporation		ensing		✓ Jerrie I	L. Chiu		
400 Morgan Lane	•			NAME			
West Haven, CT 06516 41,670							
REGISTRATION NUMBER							

526 Rec'd PET/PTO 16 JUL 2001 09 / 88 9 45 5

Attorney's Docket No. Le A 33 364

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Schoop, et al.

Serial No.: National Stage Filing of PCT/EP00/00120

Filed: Herewith

For: β-Phenylalanine Derivatives as Integrin Antagonists

BOX PCT Assistant Commissioner for Patents Washington, D.C. 20231

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the attached correspondence comprising:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
   Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];
- Copy of the International Application as filed (35 U.S.C. 371(c)(2));
- Preliminary Amendment;
- Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein; and
- Return Receipt Post Card.

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EF349742063US, addressed to:

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

16 July 2001 Date

Beatriz Alviz